Abiopharma

Lithium Argentina Reports 2026 Annual General Meeting Results

General Announcement: Reporting Share Repurchase form for Financial Management Purposes No.2

AECOM secures nine lots on UK Government Commercial Agency CPS2 Framework

Alamos Gold Extends High-Grade Mineralization Across Multiple Targets within the Island Gold District which Represent Upside as Potential Sources of Additional Higher-Grade Mill Feed

Register of shareholders, changes and capital status – final redemption of commercial papers (Series 5)

Employee Stock Option/ Share Scheme: GRANT OF SHARE OPTIONS PURSUANT TO THE CREATIVE SHARE OPTION SCHEME (2019)

General Announcement: PRICING OF OFFERING S$110M 2.50% NOTES DUE 2030 UNDER S$3B MMTN PROGRAMME OF GLL IHT PTE. LTD.

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest/ Change in Interest of Director